According to filings with the U.S. Securities and Exchange Commission, Circulogene Theranostics is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Mullen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Circulogene Theranostics
Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood in one week, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. One tube, one week, complete results. Somatic + Germline; Blood + Tissue + Buccal; DNA + RNA + MSI + PD-L1.

To learn more about Circulogene Theranostics, visit http://circulogene.com/

Contact:
Michael Mullen, Chief Executive Officer
205-521-8151
https://www.linkedin.com/in/michael-mullen-7789007/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.